UY33546A - Corticosteroides para el tratamiento del dolor de las articulaciones - Google Patents

Corticosteroides para el tratamiento del dolor de las articulaciones

Info

Publication number
UY33546A
UY33546A UY0001033546A UY33546A UY33546A UY 33546 A UY33546 A UY 33546A UY 0001033546 A UY0001033546 A UY 0001033546A UY 33546 A UY33546 A UY 33546A UY 33546 A UY33546 A UY 33546A
Authority
UY
Uruguay
Prior art keywords
pain
caused
treatment
osteoarthritis
rheumatoid arthritis
Prior art date
Application number
UY0001033546A
Other languages
English (en)
Inventor
Bodik Neil
Robert C Blank
Kumar Anjali
Michael D Clayman
Moran Mark
Original Assignee
Flexion Therapeutics
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Flexion Therapeutics filed Critical Flexion Therapeutics
Publication of UY33546A publication Critical patent/UY33546A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/44—Glucocorticosteroids; Drugs increasing or potentiating the activity of glucocorticosteroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Se proporcionan formulaciones de micropartículas de corticosteroides para el tratamiento del dolor, incluido el dolor causado por enfermedades inflamatorias como, por ejemplo, osteoartritis y artritis reumatoidea, y para enlentecer, detener o revertir el daño tisular estructural causado por enfermedades inflamatorias, por ejemplo daños a los tejidos articulares o peri articular causados por osteoartritis o artritis reumatoidea. Las formulaciones de microparticulas de corticosteroides se administran localmente como una forma de dosificación de liberación sostenida (con o sin un componente de liberación inmediata) que resulta en eficacia acompañada de efectos clínicamente insignificantes o no mensurables sobre la producción de cortisol.
UY0001033546A 2010-08-04 2011-08-03 Corticosteroides para el tratamiento del dolor de las articulaciones UY33546A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US37066610P 2010-08-04 2010-08-04

Publications (1)

Publication Number Publication Date
UY33546A true UY33546A (es) 2012-02-29

Family

ID=45559826

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001033546A UY33546A (es) 2010-08-04 2011-08-03 Corticosteroides para el tratamiento del dolor de las articulaciones

Country Status (23)

Country Link
US (8) US20120282298A1 (es)
EP (2) EP2600836B1 (es)
JP (3) JP5873492B2 (es)
KR (2) KR101927551B1 (es)
CN (2) CN107669640A (es)
AR (1) AR082471A1 (es)
AU (1) AU2011285691B2 (es)
BR (1) BR112013002601A2 (es)
CA (2) CA2956556A1 (es)
CL (1) CL2013000347A1 (es)
CO (1) CO6700827A2 (es)
ES (1) ES2799419T3 (es)
IL (1) IL224547B (es)
MX (1) MX353466B (es)
MY (1) MY171929A (es)
NZ (1) NZ607797A (es)
RU (2) RU2642279C2 (es)
SG (3) SG10201602789XA (es)
TW (2) TWI548412B (es)
UA (1) UA111162C2 (es)
UY (1) UY33546A (es)
WO (1) WO2012019009A1 (es)
ZA (1) ZA201300831B (es)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA111162C2 (uk) 2010-08-04 2016-04-11 Флекшен Терап'Ютікс, Інк. Ін'єкційна композиція ацетоніду триамцинолону для лікування болю
AU2012248038B2 (en) 2011-04-25 2015-11-12 Geneora Pharma (Shijiazhuang) Co., Ltd. Risperidone sustained release microsphere composition
CA2843139C (en) * 2011-08-04 2019-09-24 Flexion Therapeutics, Inc. Corticosteroids for the treatment of joint pain
US8927529B2 (en) 2012-01-30 2015-01-06 SpineThera Treatment of back pain by injection of microparticles of dexamethasone acetate and a polymer
TWI624262B (zh) 2013-01-23 2018-05-21 桑紐爾製藥公司 醫藥配方
ES2697696T3 (es) * 2013-03-15 2019-01-25 Oakwood Laboratories LLC Microesferas de liberación sostenida y método de producción de las mismas
WO2014153384A1 (en) * 2013-03-19 2014-09-25 Flexion Therapeutics, Inc. Corticosteroid formulations for the treatment of joint pain and methods of use thereof
JP6230691B2 (ja) 2013-03-21 2017-11-15 ユープラシア ファーマシューティカルズ ユーエスエー エルエルシーＥｕｐｒａｘｉａ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｕｓａ Ｌｌｃ 関節の炎症およびそれに関連する疼痛を治療するための注射用持続放出組成物およびその使用方法
WO2015018461A1 (fr) * 2013-08-09 2015-02-12 Genbiotech Compositions therapeutiques comprenant d'acide hyaluronique
EP3074056B1 (en) * 2013-11-27 2018-03-14 Ethicon LLC Absorbable polymeric blend compositions with precisely controllable absorption rates, processing methods, and dimensionally stable medical devices therefrom
CN111514108B (zh) * 2014-04-08 2022-11-29 帝斯曼知识产权资产管理有限公司 用于治疗关节炎病症的可生物降解的聚酯酰胺
TWI772659B (zh) 2015-01-21 2022-08-01 美商桑紐爾製藥公司 醫藥配方
CN107690333B (zh) * 2015-06-10 2021-12-17 赢创运营有限公司 制备包含人凝血因子蛋白和乳酸聚合物的粉末的方法
AR106085A1 (es) 2015-09-21 2017-12-13 Teva Pharmaceuticals Int Gmbh Formulaciones de olanzapina de liberación sostenida
TW201726145A (zh) * 2015-10-13 2017-08-01 弗萊斯恩醫療公司 用於維持皮質類固醇滑液濃度之皮質類固醇調配物
BR112018008415A2 (pt) 2015-10-27 2018-10-30 Eupraxia Pharmaceuticals Inc formulações de liberação sustentada de anestésicos locais
WO2017160818A1 (en) 2016-03-14 2017-09-21 Flexion Therapeutics, Inc. Triamcinolone acetonide formulations for joint pain in diabetics
WO2018112408A1 (en) * 2016-12-15 2018-06-21 Flexion Therapeutics, Inc. Fluticasone formulations and methods of use thereof
CN106727358A (zh) * 2017-01-24 2017-05-31 广州帝奇医药技术有限公司 阿立哌唑及其衍生物的缓释组合物与该缓释组合物的制备方法
CN106983733A (zh) * 2017-03-08 2017-07-28 江苏富泽药业有限公司 曲安奈德plga缓释微球注射剂、其制备方法及其在制备治疗骨关节炎疼痛药物中的应用
EP3595776A4 (en) * 2017-03-17 2020-09-30 Flexion Therapeutics, Inc. FLUTICASONE SUSTAINED-RELEASE FORMULATIONS AND THEIR PROCEDURES FOR USE
CA3057438A1 (en) 2017-03-20 2018-09-27 Teva Pharmaceuticals International Gmbh Sustained release olanzapine formulaitons
KR102101969B1 (ko) * 2017-09-06 2020-04-22 (주)인벤티지랩 목시덱틴을 포함하는 마이크로 입자 및 이의 제조 방법
US20190336511A1 (en) * 2018-05-02 2019-11-07 Georgiy Brusovanik Treatment for Inflammation and Pain with Reduced Gastro-Intestinal Side Effects Combining Methylprednisolone, Paracetamol, and Lansoprazole
BR112021000316A2 (pt) 2018-07-09 2021-04-06 Taiwan Liposome Co. Ltd Métodos para reduzir complicações de esteroide intra-articular
RU2703257C1 (ru) * 2018-12-04 2019-10-16 Закрытое акционерное общество "СКАЙ ЛТД" Способ лечения воспалительных процессов суставов и простатита
CN109700770B (zh) * 2019-01-31 2021-02-12 浙江圣兆药物科技股份有限公司 一种曲安奈德微球制剂及其制备方法
EP3943073A4 (en) * 2019-03-19 2023-01-04 Regenbiotech, Inc. BIODEGRADABLE POLYMERIC MICROPARTICLE WITH A STEROID-BASED DRUG AND PROCESS FOR ITS PRODUCTION
KR102377975B1 (ko) * 2019-03-19 2022-03-23 (주)리젠바이오텍 스테로이드계 약물을 포함하는 생분해성 고분자 미세입자 및 이의 제조 방법
CN113795246B (zh) * 2019-05-06 2024-10-11 福多兹制药公司 用于治疗关节疼痛和炎症的可注射缓释制剂
EP3976106A4 (en) * 2019-05-31 2023-01-11 DOSE Medical Corporation BIOERODABLE POLYESTER SPINE IMPLANTS AND METHODS OF USE THEREOF
CN110237052B (zh) * 2019-07-11 2021-07-13 苏州大学 一种醋酸曲安奈德缓释微球及其制备方法
CN111803647A (zh) * 2020-08-14 2020-10-23 山东谷雨春生物科技有限公司 一种治疗退行性关节炎的药物及其制备方法
US20240100012A1 (en) 2021-01-18 2024-03-28 Mark Hasleton Pharmaceutical dosage form
GB202104224D0 (en) 2021-03-25 2021-05-12 Medincell Pharmaceutical composition
EP4313021A1 (en) * 2021-03-26 2024-02-07 The Regents Of The University Of California Immunoregulatory microparticles for modulating inflammatory arthritides
US20240197637A1 (en) 2021-04-16 2024-06-20 Fondazione Istituto Italiano Di Tecnologia Polymeric microparticles for the local treatment of chronic inflammatory diseases
US20240277654A1 (en) 2021-07-06 2024-08-22 Mark Hasleton Treatment of serotonin reuptake inhibitor withdrawal syndrome
WO2024085581A1 (ko) * 2022-10-17 2024-04-25 (주)인벤티지랩 염증성 질환의 치료 또는 예방을 위한 서방형 주사용 조성물 및 이의 제조 방법

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4293539A (en) 1979-09-12 1981-10-06 Eli Lilly And Company Controlled release formulations and method of treatment
US4530840A (en) * 1982-07-29 1985-07-23 The Stolle Research And Development Corporation Injectable, long-acting microparticle formulation for the delivery of anti-inflammatory agents
US5700485A (en) * 1992-09-10 1997-12-23 Children's Medical Center Corporation Prolonged nerve blockade by the combination of local anesthetic and glucocorticoid
CA2172508C (en) 1993-10-22 2005-08-23 Jeffrey L. Cleland Method for preparing microspheres comprising a fluidized bed drying step
EP0998917A1 (en) 1993-11-19 2000-05-10 Alkermes Controlled Therapeutics Inc. II Preparation of biodegradable microparticles containing a biologically active agent
EP1010435B1 (en) 1997-09-05 2010-11-03 Maruho K.K. Nanocapsule preparations for treating intraarticular diseases
TW577758B (en) * 1997-10-27 2004-03-01 Ssp Co Ltd Intra-articular preparation for the treatment of arthropathy
JPH11222425A (ja) * 1997-10-27 1999-08-17 Ss Pharmaceut Co Ltd 関節疾患治療用関節内投与製剤
US6726918B1 (en) * 2000-07-05 2004-04-27 Oculex Pharmaceuticals, Inc. Methods for treating inflammation-mediated conditions of the eye
US6824822B2 (en) 2001-08-31 2004-11-30 Alkermes Controlled Therapeutics Inc. Ii Residual solvent extraction method and microparticles produced thereby
WO2002036168A1 (fr) 2000-11-06 2002-05-10 Asahi Kasei Kabushiki Kaisha Particules cellulosiques destinees a des preparations pharmaceutiques
KR100446101B1 (ko) 2000-12-07 2004-08-30 주식회사 삼양사 수난용성 약물의 서방성 제형 조성물
ATE361057T1 (de) 2000-12-21 2007-05-15 Alrise Biosystems Gmbh Verfahren umfassend einen induzierten phasenübergang zur herstellung von hydrophobe wirkstoffe enthaltenden mikropartikeln
US20040022853A1 (en) 2001-04-26 2004-02-05 Control Delivery Systems, Inc. Polymer-based, sustained release drug delivery system
JP2006503865A (ja) * 2002-09-30 2006-02-02 アキュスフィア， インコーポレイテッド 吸入のための徐放性の多孔性微粒子
US20040121009A1 (en) 2002-10-17 2004-06-24 Alkermes Controlled Therapeutics, Inc. Method of modifying the release profile of sustained release compositions
AU2004222340B2 (en) 2003-03-14 2009-11-12 Intersect Ent, Inc. Sinus delivery of sustained release therapeutics
US20040224030A1 (en) * 2003-05-06 2004-11-11 Shastri Venkatram R. Microsphere delivery systems
EP1643970A2 (en) 2003-06-09 2006-04-12 Nastech Pharmaceutical Company Inc. Compositions and methods for enhanced mucosal delivery of growth hormone
CN1856296A (zh) * 2003-09-30 2006-11-01 阿库斯菲尔公司 可注射的、口服、或局部用缓释药物制剂
US7456254B2 (en) * 2004-04-15 2008-11-25 Alkermes, Inc. Polymer-based sustained release device
US8119154B2 (en) * 2004-04-30 2012-02-21 Allergan, Inc. Sustained release intraocular implants and related methods
US20090324678A1 (en) * 2004-07-16 2009-12-31 Spinal Restoration, Inc. Methods and kits for treating joints and soft tissues
WO2007030545A2 (en) 2005-09-07 2007-03-15 Southwest Research Institute Biodegradable microparticle pharmaceutical formulations exhibiting improved release rates
US7261529B2 (en) 2005-09-07 2007-08-28 Southwest Research Institute Apparatus for preparing biodegradable microparticle formulations containing pharmaceutically active agents
US7758778B2 (en) 2005-09-07 2010-07-20 Southwest Research Institute Methods for preparing biodegradable microparticle formulations containing pharmaceutically active agents
US9693967B2 (en) * 2005-09-07 2017-07-04 Southwest Research Institute Biodegradable microparticle pharmaceutical formulations exhibiting improved released rates
WO2007084418A2 (en) 2006-01-13 2007-07-26 Surmodics, Inc. Microparticle containing matrices for drug delivery
US20070298073A1 (en) * 2006-06-23 2007-12-27 Allergan, Inc. Steroid-containing sustained release intraocular implants and related methods
US20080248122A1 (en) * 2006-10-06 2008-10-09 Baxter International Inc. Microencapsules Containing Surface-Modified Microparticles And Methods Of Forming And Using The Same
US20080317805A1 (en) * 2007-06-19 2008-12-25 Mckay William F Locally administrated low doses of corticosteroids
EP2195011A4 (en) * 2007-08-23 2010-12-01 Genzyme Corp TREATMENT WITH CALLICINE INHIBITORS
US20110206773A1 (en) 2008-05-20 2011-08-25 Yale University Sustained delivery of drugs from biodegradable polymeric microparticles
US20110311630A1 (en) 2008-06-09 2011-12-22 Boehringer Ingelheim International Gmbh Novel embedment particles for inhalation
EP2331082B1 (en) * 2008-09-11 2021-01-06 Evonik Corporation Solvent extraction microencapsulation with tunable extraction rates
US20100189763A1 (en) 2009-01-23 2010-07-29 Heather Nettles Controlled release systems from polymer blends
EP2512487A4 (en) 2009-12-15 2013-08-07 THERAPEUTIC POLYMERNANOPARTICLES WITH CORTICOSTEROIDS AND METHOD FOR THE PRODUCTION AND USE THEREOF
UA111162C2 (uk) 2010-08-04 2016-04-11 Флекшен Терап'Ютікс, Інк. Ін'єкційна композиція ацетоніду триамцинолону для лікування болю

Also Published As

Publication number Publication date
CA2956556A1 (en) 2012-02-09
CA2807150C (en) 2017-03-14
US20170182068A1 (en) 2017-06-29
TW201219039A (en) 2012-05-16
SG187665A1 (en) 2013-03-28
ES2799419T3 (es) 2020-12-17
CN103260603A (zh) 2013-08-21
SG10201602789XA (en) 2016-05-30
KR20130093101A (ko) 2013-08-21
US9949987B2 (en) 2018-04-24
US20170135957A1 (en) 2017-05-18
NZ607797A (en) 2014-12-24
CO6700827A2 (es) 2013-06-28
EP3701941A1 (en) 2020-09-02
RU2013109362A (ru) 2014-09-10
US20140242170A1 (en) 2014-08-28
RU2642279C2 (ru) 2018-01-24
UA111162C2 (uk) 2016-04-11
TWI630001B (zh) 2018-07-21
MX2013001433A (es) 2013-06-03
JP2019059752A (ja) 2019-04-18
US20180311260A1 (en) 2018-11-01
MX353466B (es) 2018-01-12
JP2013535489A (ja) 2013-09-12
IL224547B (en) 2020-09-30
CN103260603B (zh) 2017-11-10
AU2011285691B2 (en) 2015-10-01
EP2600836A1 (en) 2013-06-12
US9555048B2 (en) 2017-01-31
US10624905B2 (en) 2020-04-21
MY171929A (en) 2019-11-07
US20120288534A1 (en) 2012-11-15
EP2600836B1 (en) 2020-04-22
WO2012019009A1 (en) 2012-02-09
JP5873492B2 (ja) 2016-03-01
US20140356437A1 (en) 2014-12-04
ZA201300831B (en) 2014-10-29
JP2016028070A (ja) 2016-02-25
AU2011285691A1 (en) 2013-03-21
CL2013000347A1 (es) 2013-09-06
BR112013002601A2 (pt) 2016-06-07
KR101927551B1 (ko) 2018-12-10
US9555047B2 (en) 2017-01-31
CN107669640A (zh) 2018-02-09
US20120282298A1 (en) 2012-11-08
SG10201607891VA (en) 2016-11-29
KR20180132159A (ko) 2018-12-11
TW201703762A (zh) 2017-02-01
EP2600836A4 (en) 2014-01-15
CA2807150A1 (en) 2012-02-09
AR082471A1 (es) 2012-12-12
US8828440B2 (en) 2014-09-09
RU2018100114A (ru) 2019-02-20
TWI548412B (zh) 2016-09-11
US20150025050A1 (en) 2015-01-22

Similar Documents

Publication Publication Date Title
UY33546A (es) Corticosteroides para el tratamiento del dolor de las articulaciones
CL2019000431A1 (es) Tetrahidro-pirido[3,4-b]indoles moduladores de receptores de estrógenos y usos de los mismos. (divisional solicitud 201700814)
UY32989A (es) Coposiciones terapéuticas concentradas de fosfolípidos
GT200600297A (es) Nuevos anticuerpos anti-madcam
CU20150163A7 (es) DERIVADOS DE 5-HETEROARIL-4-FENIL-4,5-DIHIDROPIRROLO(3,4-c)PIRAZOL-6-ONA ACTIVOS COMO INHIBIDORES DE BET
CL2013000063A1 (es) Un método para tratar a un sujeto que comprende administrar n-etil-n-fenil1,2-dihidroxi-4-hodroxi-5-cloro-1-metil-2-oxoquinolina-3-carboxamida opcionalmente deuterada, para el tratamiento de una enfermedad autoinmunitaria; una mezcla de los mismos; composición farmaceutica y su proceso de preparacion.
BR112012023021A2 (pt) compostos de indazol e seus usos
CO6531427A2 (es) Composiciones de corticosteriodes administradas oralmente
PE20150631A1 (es) Formas cristalinas de un modulador del receptor androgenico
PE20180399A1 (es) Composiciones transdermicas de ibuprofeno y metodos de uso de las mismas
BR112015020389A8 (pt) compostos carbazol úteis como inibidores de bromodomínio, seu uso, bem como composição e produto farmacêuticos compreendendo os mesmos
UY33029A (es) Antagonistas de espiro-oxindol de mdm2
CO6771417A2 (es) Antagonistas del receptor de ácido lisofosfatidico y su uso en el tratamiento de fibrosis
GT201400069A (es) Composiciones farmaceuticas
CL2008002999A1 (es) Uso de una composicion farmeceutica que comprende trns-clominefo para preparar un medicamenteo util en el ratamiento de recuccion de los niveles de glucosa en ayunas en un varon.
CO6491060A2 (es) Compuestos y composiciones para el tratamiento de enfermedades parasitarias
BR112014020271A8 (pt) Composição farmacêutica e métodos para diminuir a frequência de micção em paciente
BR112017016087A2 (pt) formulações para coxim articular adiposo e métodos de uso das mesmas
CO7141430A2 (es) Formulaciones vesiculares para uso en el tratamiento del dolor o movilidad reducida de una articulación
WO2014107730A3 (en) Use of fatty acid niacin conjugates for treating diseases
CO2019008053A2 (es) Agente terapéutico para enfermedades del hígado
BR112015029894A2 (pt) forma de dosagem farmacêutica sólida
AR083095A1 (es) Cocristal de aprepitant l-prolina y composicion farmaceutica
BR112015001627A2 (pt) composição farmacêutica, respectivos usos e método para diminuir a frequência de micção
NI201200196A (es) Agentes terapéuticos 976

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20200820